Richard Allen

Featured in: Favicon

ft.com

biomedcentral.com Favicon

aao.org

bmcpsychology.biomedcentral.com

Articles

Many Patients Treated With Teprotumumab Will Eventually Need Re-Treatment

Jan 10, 2025 | aao.org | Richard Allen

JAN 10, 2025 Oculoplastics/Orbit In this study, nearly 25% of patients who were given a full course of teprotumumab therapy for thyroid eye disease (TED) eventually needed re-treatment. Study DesignThis was a retrospective study of 119 patients with TED who completed an uninterrupted course of teprotumumab therapy at 1 of 3 US-based institutions.
Choroidal Thickening Appears to Be Greater in Active vs Inactive Thyroid Eye Disease

Aug 28, 2024 | aao.org | Richard Allen

Subfoveal choroidal thickness (SFCT), as measured with swept-source OCT (SS-OCT), may be a potential marker for measuring disease activity in thyroid eye disease (TED). Study Design This cross-sectional study, conducted at a single hospital in China, enrolled 30 patients with TED and 38 age- and sex-matched healthy controls. The clinical activity score (CAS) was used to grade disease activity in the TED group (active or inactive disease).
Prescribing Opioids for Ophthalmic Surgical Pain Can Increase the Risk of Complications

Aug 22, 2024 | aao.org | Richard Allen

Introducing an opioid into the post–ophthalmic surgery treatment mix can potentially increase the chances of hospitalization, opioid abuse/dependence, and all-cause mortality. Study Design De-identified administrative claims data from the OptumLabs Data Warehouse were used to identify 1,577,692 adults who had a procedure code for an ophthalmic surgery during a 6.5-year period (anterior-segment, cornea, oculoplastics, pediatric ophthalmology, or retina surgery).
Early Response Seen With Teprotumumab for TED Appears to Wane in the Long Term

Aug 6, 2024 | aao.org | Richard Allen

Investigators studied the long-term proptosis reactivation/recurrence rate in patients who had completed a full course of teprotumumab treatment for active thyroid eye disease (TED). Study Design This was a retrospective review of records from 21 patients with active TED treated at Cole Eye Institute/Cleveland Clinic. Three patients received 7 infusions of teprotumumab rather than the usual 8 infusions.
Menstrual Irregularities Are Seen in Premenopausal Women Taking Teprotumumab

Jul 1, 2024 | aao.org | Richard Allen

A study specifically designed to assess the effects of teprotumumab therapy on menstruation has found a high rate of menstrual irregularities. However, these effects largely reversed after 3 months of treatment cessation. Study Design This was a retrospective review of data from 12 female patients with baseline regular menstruation (mean age 38.3 years [range 25–53 years]) who completed 8 infusions of teprotumumab for active thyroid eye disease (TED).
Nodular Fasciitis Mimicking a Dermoid Cyst

Jun 13, 2024 | aao.org | Richard Allen

It is easy to get lulled into thinking that all superior medial masses in young children are dermoid cysts. Here, Dr. Richard Allen describes a case where the child was initially thought to have a dermoid cyst, but at follow-up had induced astigmatism from the mass, which is not typical for a dermoid cyst. The mass proved to be nodular fasciitis, which was removed via complete excision. Financial Disclosures: Dr. Richard Allen discloses no financial relationships.
Adverse Events Are Commonly Seen With Teprotumumab Therapy for TED

Apr 15, 2024 | aao.org | Richard Allen

While teprotumumab has efficacy in treating thyroid eye disease (TED), particularly moderate-to-severe disease, adverse events (AEs) related to treatment are common. Study Design This was a multicenter retrospective cohort study of 131 consecutive patients with TED treated with teprotumumab between February 2020 and October 2022.
Upper Blepharoplasty Marking

Apr 4, 2024 | aao.org | Richard Allen

In this video, Dr. Richard Allen discusses methods for marking an upper blepharoplasty, including the pinch technique and using calipers, and demonstrates his preferred method. Whichever technique is chosen, it is key that the eyelid crease and the amount of skin remaining be symmetrical, and there should be enough skin to prevent postoperative lagophthalmos. Financial Disclosures: Dr. Richard Allen discloses no financial relationships.
Conjunctival Cautery for Conjunctivochalasis

Dec 14, 2023 | aao.org | Richard Allen

Treatment of conjunctivochalasis has traditionally involved resection of the redundant conjunctiva and suturing of the defect. In this video, Dr. Richard Allen demonstrates the use of high-temperature thermal cautery to apply a diffuse superficial injury to the area of the redundant conjunctiva. This is a quick, cost-effective procedure which requires minimal instrumentation. Financial Disclosures: Dr. Richard Allen discloses no financial relationships.
Treating otitis media in children with CNLDO could require T-tube placement

Dec 11, 2023 | aao.org | Richard Allen

Children with congenital nasolacrimal duct obstruction (CNLDO) who need probing and intubation (P&I) for otitis media (OM) are at higher risk of multiple tympanostomy tube (T-tube) placements in the ear later on. Study design This study was a prospective case series involving 92 consecutive children aged 10–24 months diagnosed with CNLDO who were treated with P&I of the lacrimal system at a single institution between January 2006 and December 2014.